Introduction {#s1}
============

Expression quantitative trait loci (eQTLs) have identified important functions for noncoding single-nucleotide polymorphisms (SNPs) across the genome---some of which have been associated with drug response phenotypes identified during genome-wide association studies (GWAS) ([@B5]; [@B21]; [@B4]; [@B15]; [@B6]). Furthermore, some of those SNPs are associated with variation in gene expression only in response to an environmental stimulus such as drug exposure, but are not associated with variation in gene expression under basal conditions ([@B26]; [@B3]; [@B20]; [@B2]; [@B11]). However, molecular mechanisms by which SNPs are associated with variation in gene expression only after drug or xenobiotic exposure remain unclear. We have identified SNPs that are distant from ligand-activated transcription factor (TF) binding sites that can influence target gene expression in a SNP genotype-by-ligand--dependent fashion. We refer to those SNPs as pharmacogenomic eQTLs (PGx-eQTLs), DNA sequence variation that might have important clinical and pharmacotherapeutic implications. In this report, we will define a PGx-eQTL as a genetic locus that is associated with interindividual variation in transcription regulation that results in altered gene expression after drug or xenobiotic exposure ([@B41], [@B37]; [@B67]; [@B17]).

Obviously, SNPs can create/disrupt canonical TF-binding motifs ([@B26]; [@B3]; [@B20]), but our previous studies identified several examples of SNPs that map hundreds of base pairs (bp) distant from ligand-activated TF binding sites that could influence TF binding in a SNP genotype-by-drug exposure--dependent manner ([@B41], [@B37]; [@B67]; [@B17]; [@B51]). One of those studies identified a PGx-eQTL for the aryl hydrocarbon receptor (AHR), a ligand-activated TF that is an important environmental modulator for several critical pathways and processes, including chemical toxicology, immune stimulation, cancer, and the kynurenine pathway ([@B55]; [@B38]; [@B47]). In that study, we identified a SNP (rs2470893) in the promoter of the cytochrome P450 1A1 (*CYP1A1*) gene that was associated with variation in differential expression of *CYP1A1* after exposure to the AHR ligand 3-methylcholanthrene (3-MC) as compared with vehicle treatment, even though rs2470893 was not an eQTL for *CYP1A1* prior to exposure to 3-MC. However, the rs2470893 SNP was distant from a canonical AHR response element (AHRE; also often referred to as a xenobiotic response element or a dioxin response element)---the DNA sequence recognized and bound by ligand-activated AHR (5′-CACGC-3′) ([@B37]). CYP1A1 plays an important role in the metabolism of xenobiotics and drugs, so the rs2470893 SNP genotype could alter individual response to drugs that are metabolized by CYP1A1.

That observation raised the possibility that SNPs at a distance from AHREs might influence AHR ligand-dependent target gene expression and could have important implications for health, disease, and variation in drug response. However, it is unclear how prevalent PGx-eQTLs are---i.e., how many SNPs are not eQTLs in the absence of ligand exposure and do not create/destroy a canonical AHRE binding site but, nonetheless, demonstrate this SNP-by-drug interaction. In the present study, we queried SNPs at a distance from AHREs across the genome---SNPs beyond the previously described *CYP1A1* SNP---in an effort to identify additional novel AHR ligand-dependent *cis* PGx-eQTLs using a panel of human lymphoblastoid cell lines (LCLs)---Epstein-Barr virus--transformed B cells. We have previously generated dense genomic data for this panel of cell lines derived from a large number of individual subjects. We identified 10 novel *cis* PGx-eQTLs and then further investigated those loci in additional cell types to identify possible SNP-by-ligand--dependent effects using luciferase reporter gene assays. Importantly, some of the *cis* PGx-eQTLs identified had previously been associated with clinical and pharmacotherapeutic response phenotypes, indicating that the findings reported in this work might provide insight into individual differences in patient response to drug therapy.

In summary, we systematically identified and tested SNPs across the genome that did not create/destroy AHREs and were associated with variation in AHR ligand--dependent expression but were not associated with variation in the absence of AHR ligand exposure. These observations suggest that knowledge of eQTLs under basal conditions is insufficient to fully understand the functional implications of many common polymorphisms, and that SNPs at a distance from ligand-activated TF binding sites may play an important role in interindividual variation in response to pharmacological and environmental agents that are ligands for ligand-activated TFs.

Materials and Methods {#s2}
=====================

 {#s3}

### The Human Variation Panel. {#s4}

The human variation panel of 300 LCLs---100 Han Chinese-American, 100 African-American, and 100 Caucasian-American---was generated from immortalized B cells purchased from the Coriell Institute (Camden, NJ). SNP genotype data and baseline microarray expression data were generated by Dr. L.W. and are available for all LCLs in the Human Variation Panel (Gene Expression Omnibus SuperSeries accession number GSE24277). This panel has proven extremely useful for generating and testing PGx hypotheses ([@B33]; [@B49]; [@B19]; [@B40], [@B39], [@B36]).

### Cell Cultures. {#s5}

LCLs were cultured in RPMI 1640 with 15% FBS and 1% penicillin/streptomycin. HMC3 (CRL-3304; American Type Culture Collection) and HepG2 (HB-8065; American Type Culture Collection) cells were cultured in EMEM with 10% FBS and 1% penicillin/streptomycin. All cells were cultured at 37°C with 5% CO~2~. For all treatment exposure experiments, cells were treated with 1 *μ*M 3-methylcholanthrene (3-MC; Enzo Life Sciences, Farmingdale, NY), 1 *μ*M N-\[2-(3H-indol-3-yl)ethyl\]-9-isopropyl-2-(5-methyl-3-pyridyl)purin-6-amine (GNF-351; MilliporeSigma, Burlington, MA), or 0.1% DMSO final concentration (vehicle) and were cultured for 24 hours. These conditions were previously optimized ([@B37]).

### RNA Sequencing. {#s6}

GM17212, GM17223, GM17229, GM17240, GM17264, GM17276, GM17281, and GM17295 LCLs from the human variation panel were used to perform the RNA-seq studies. Metadata, including sex of the LCL donors, AHR expression levels in each LCL, and rs2470893 (*CYP1A1 cis* PGx-eQTL) SNP genotype status of each LCL studied, are provided in [Supplemental Table 1](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1). Cells were harvested by pelleting at 300 g for 5 minutes at 4°C and were washed with ice-cold phosphate-buffered saline before extracting RNA using the miRNeasy RNA extraction kit per manufacturer instructions (Qiagen, Germantown, MD). Sample RNA integrity numbers were between 7 and 10 (average = 9.45, median = 9.6) ([Supplemental Table 2](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)). RNA-seq libraries were prepared using the TruSeq RNA Library Prep Kit v2 (Illumina, San Diego, CA), and paired-end sequencing was performed on an Illumina HiSEq 4000. FastQC ([@B11]) was used to determine RNA-sequencing quality. RNA-sequencing data were aligned to the hg38 human genome using TopHat (2.0.14) ([@B24]). Raw counts were calculated using Subread (1.4.6) ([@B35]). RSeQC (2.4.6) was used for alignment quality control ([@B62]). RNA-seq quality control measures were within expectations (49%--50% GC content, sequencing quality score ≥32% and ≥80% reads concordantly mapped) ([Supplemental Table 2](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)). EdgeR was used to identify genes differentially expressed after 3-MC or GNF-351 treatment compared with vehicle ([@B52]). EdgeR-normalized log of counts per million (cpm) demonstrated a high degree of correlation between duplicates (*R*^2^ \> 0.992) ([Supplemental Table 2](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)).

### Chromatin Immunoprecipitation Antibody Characterization. {#s7}

The AHR antibody (D5S6H-lot1; Cell Signaling Technologies, Danvers, MA) that was used for chromatin immunoprecipitation (ChIP)-seq was characterized using primary and secondary characterization modes, as suggested by ENCODE guidelines ([@B31]). Immunoblot of whole-cell lysates was used as the primary characterization and identified a single crisp band that accounted for 81% (S.E. 3.9%) of the total immunoreactivity per lane at the expected molecular weight (∼100 kDa) for lysates from seven LCLs ([Supplemental Fig. 1A](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)). Both immunoblot and ChIP-quantitative polymerase chain reaction (qPCR) at the *CYP1B1* promoter---a known and prototypic binding region for AHR ([@B54]; [@B64])---were decreased by ≥90% after AHR-pooled small interfering RNA knockdown (Dharmacon, Lafayette, CO) for secondary characterization of the antibody in HMC3 cells ([Supplemental Fig. 1, B and C](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)). An intergenic region on chromosome 19 was used as the negative locus for all ChIP-qPCR.

### ChIP Sequencing. {#s8}

Cells were incubated at room temperature for 10 minutes and cross-linked with 1% methanol-free formaldehyde for 10 minutes, and the reaction was quenched with 0.125 M glycine for 5 minutes. Twenty million cross-linked cells were pelleted, and the pellet was washed once with ice-cold Tris-buffered saline. Pelleted cells were frozen at −80°C, and ChIP-seq was carried out, as previously described ([@B66]). The characterized AHR antibody (D5S6H-lot 1) was used to perform AHR ChIP-seq. FastQC was used to assess sequencing quality. Sequences were aligned to human genome version 19 (hg19) using Burrows--Wheeler Aligner, and duplicates were removed. Model-based analysis of ChIP-Seq (MACS2) was used to identify peaks ([@B65]). The ChIP-seq peak detection threshold (q) was set to 0.01. The MEME suite ([@B1]) was used to search for *de novo* motifs and compare those motifs with the motifs in the *Homo sapiens* Comprehensive Model Collection (HOCOMOCOv10) database ([@B29]). The HOMER Motif Analysis Software ([@B16]) was used to quantify the number of times a motif was identified in peaks. The ChromHMM ([@B22]; [@B9]) track for a LCL (GM12878) was used to identify the chromatin state of regions that contained AHR-binding peaks.

### Quantitative Reverse-Transcription Polymerase Chain Reaction. {#s9}

Total RNA was collected from LCLs using the Zymo Quick RNA Mini-prep kit (Zymo Research, Irvine, CA). RNA was quantified by NanoDrop, and 50--200 ng total RNA was used for quantitative reverse-transcription polymerase chain reaction (qRT-PCR) assays (based on baseline expression of the genes and the efficiency of the qRT-PCR primers). The Power SYBR Green RNA-to-Ct 1-Step Kit (Applied Biosystems, Foster City, CA) was used for all qRT-PCR assays, except for CYP1B1, in which a PrimeTime qPCR probe (Integrated DNA Technologies, San Diego, CA) was used. Primers and probes used for qRT-PCR are listed in [Supplemental Table 3](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1). Differential expression of a gene after 3-MC or GNF-351 treatment compared with vehicle was calculated using the comparative Ct method relative to *β* actin ([@B53]). Experiments were carried out at least twice in duplicate or triplicate with a minimum of six different LCLs.

### Data Analysis and Statistical Analysis. {#s10}

Bedtools was used to compare the relative location of different genomic elements, including genes, AHR ChIP-seq--binding peaks, SNPs, ChromHMM-defined chomatin states ([@B22]; [@B9]), and chromatin states from the epigenome roadmap ([@B30]).

A Spearman correlation coeficient was used to test for correlation of SNPs with variation in differential gene expression following exposure to 3-MC or GNF-351 relative to vehicle and was tested for significance under the Student's *t* distribution with an *α* of 0.1. An *α* of 0.1 allowed us to detect a correlation of 0.72 with 70% power. A two-sided Student's *t* test was used to test the null hypothesis that the mean of differential gene expression after ligand treatment relative to vehicle was equal for two groups for qRT-PCR and luciferase assays. The null hypothesis was rejected when the calculated *P* value was less than 0.05. Statistical analyses were done in Excel and R, and plots were generated in R.

### Luciferase Reporter Gene Assays. {#s11}

Luciferase reporter gene constructs were prepared by cloning the region of interest into the pGL4 (E6651) backbone (Promega, Madison, WI). To investigate SNP function, regions were cloned from LCLs that contained SNPs of interest, but did not differ at any other SNP, unless otherwise noted, or were synthesized by GENEWIZ (South Plainfield, NJ). The FastStart Taq DNA polymerase kit (Roche, Indianapolis, IN) with or without the GC-RICH solution, the KAPA HiFi HotStart ReadyMixPCR Kit (Kapa Biosystems, Wilmington, MA), the Platinum Taq DNA Polymerase kit (Thermo Fisher Scientific, Waltham, MA), or the GC-RICH PCR system (Roche) was used to amplify the regions of interest.

Luciferase plasmids were cotransfected into cells with a 1:10 ratio of pRL renilla, which was used as a transfection control vector (E2231; Promega). Thermo Fisher Scientific (Morristown, NJ) Lipofectamine 3000 or Lipofectamine 2000 (HMC3 and HepG2) or the Lonza nucleofector kit V (LCLs) were used as transfection methods per manufacturer instructions. Twelve hours post-transfection, cells were exposed to 3-MC, GNF-351, or 0.1% DMSO (vehicle). Twenty-four hours post-treatment, medium was aspirated from wells and cells were washed with PBS (HMC3 and HepG2), or cells were pelleted at 2500 rpm and washed with PBS (LCLs) before resuspending in 1× passive lysis buffer (Promega). The Promega Dual-Luciferase Reporter Assay system was used for luciferase detection. Luciferase assays were carried out per manufacturer instructions. The ratio of luciferase to renilla (transfection control vector) was used to normalize transfection efficiency before calculating the fold change ([@B7]). All luciferase assays were carried out at least twice with a minimum of six replicates.

Results {#s12}
=======

Experimental Strategy for the Identification and Validation of Putative AHR PGx-eQTLs {#s13}
-------------------------------------------------------------------------------------

We reported previously that a SNP (rs2470893) at a distance from an AHRE in the promoter of the *CYP1A1* gene was a *cis* PGx-eQTL for *CYP1A1* after treatment with an exogenous AHR agonist, 3-MC, even though it was not an eQTL in the absence of 3-MC exposure ([@B37]). In the present series of studies, to test the hypothesis that many other SNPs across the genome that are near AHR-regulated genes but that do not create/destroy AHREs---the DNA sequence recognized and bound by ligand-activated AHR---might influence variation in AHR ligand-dependent gene expression, we performed RNA-seq using eight LCLs---four homozygous wild-type and four homozygous variants for the rs2470893 SNP. We chose LCLs based on their rs2470893 SNP genotype so we could use that SNP as a *cis* PGx-eQTL positive control before using the RNA-seq data to test for novel *cis* PGx-eQTLs at additional genomic loci across the genome.

We understood that, with eight cell lines, we were underpowered to test possible associations of all SNPs across the genome that displayed differential gene expression following AHR ligand exposure as compared with vehicle. Therefore, we used a highly focused approach that allowed us to identify *cis* PGx-eQTLs by testing associations between SNPs surrounding known AHR binding sites near genes that were differentially expressed after exposure to the AHR agonist 3-MC or the AHR antagonist N-\[2-(3H-indol-3-yl)ethyl\]-9-isopropyl-2-(5-methyl-3-pyridyl)purin-6-amine (GNF-351) as compared with vehicle. Our approach to the identification of *cis* PGx-eQTLs included two phases: a hypothesis-generating phase that identified putatitve *cis* PGx-eQTLs, and a functional genomics phase designed to test the validity and generalizability of the putative *cis* PGx-eQTLs identified during the first phase.

The first phase---the hypothesis-generating phase---included four steps that were designed to identify putative *cis* PGx-eQTLs. As an initial step, we identified genes that were highly differentially expressed \[false discovery rate (FDR) ≤0.05, \|fold change\| ≥2\] as determined by RNA-seq after treatment with the AHR agonist 3-MC or the AHR antagonist GNF-351 as compared with vehicle ([Fig. 1](#F1){ref-type="fig"}, Step 1a). In parallel, we identified AHR binding sites throughout the genome by performing ChIP-seq using a single LCL ([Fig. 1](#F1){ref-type="fig"}, Step 1b). We next identified which of the highly differentially expressed genes contained at least one AHR-binding peak within 50 kilobase (kb) of the gene ([Fig. 1](#F1){ref-type="fig"}, Step 2) to identify genes that were most likely to be directly regulated by AHR. Next, SNPs within 500 bp of AHR-binding peaks that were within 50 kb of the differentially expressed genes ([Fig. 1](#F1){ref-type="fig"}, Step 3) were tested for association (Spearman's rank-order correlation) with variation in differential gene expression after treatment with 3-MC or GNF-351 ([Fig. 1](#F1){ref-type="fig"}, Step 4). We selected a distance of 500 bp from a given AHR peak because all previously identified PGx-eQTLs have been within this distance and we were underpowered to investigate the association of all SNPs with variation in ligand-dependent gene expression. Only SNPs that had a minor allele frequency (MAF) \>0.25 were considered for association because 0.25 was a MAF at which we were reasonably likely to include at least one homozygous variant LCL by chance among the eight LCLs based on Hardy--Weinberg equilibrium predictions. SNPs were excluded from consideration if they were eQTLs without treatment or if baseline eQTL information in LCLs was missing, as indicated by GTEx ([@B4]). SNPs that were associated with variation in gene expression were tested for linkage disequilibrium, and all linked SNPs (*R*^2^ \> 0.8) were considered part of a single locus. Therefore, one *cis* PGx-eQTL could include multiple SNPs and/or multiple AHR-binding peaks.

![PGx-eQTL analysis scheme. A PGx pipeline was developed to merge RNA-seq, ChIP-seq, and SNP-genotype data to identify putative PGx-eQTLs. As a first step, we identified the top differentially expressed genes \[\|Log2(fold change)\| \>1 and FDR \<0.05\] from our RNA-seq analyses for eight LCLs that were treated with 0.1% DMSO, 1 *µ*M 3-MC, or 1 *µ*M GNF-351 in duplicate (Step 1a). In parallel, we identified AHR-binding regions from AHR ChIP-seq analysis performed for one of the LCLs used in the RNA-seq studies (Step 1b). We next determined which of the top differentially expressed genes had AHR-binding peaks within 50 kb of the gene (Step 2) and identified those peaks that had SNPs with a MAF \>0.25 that mapped within 500 bp of AHR ChIP-seq peaks (Step 3). We then identified putative PGx-eQTLs by testing the association of the SNPs from Step 3 with the differential expression of the nearby differentially expressed gene with the Spearman rank correlation and tested for significance under a two-tailed *t*-distribution (Step 4). We validated the putative PGx-eQTLs identified in additional LCLs (Step 5) and functionally validated them with luciferase reporter gene assays (Step 6).](dmd.119.087312f1){#F1}

The second phase---the functional genomics phase of the study---consisted of two steps designed to test the validity of the *cis* PGx-eQTLs and examine their possible function in additional cell types. Therefore, we first tested the putative *cis* PGx-eQTLs that had been identified during the hypothesis-generating phase by qRT-PCR in additional LCLs that were selected based on known SNP genotypes for each of the *cis* PGx-eQTLs ([Fig. 1](#F1){ref-type="fig"}, Step 5). Finally, we examined the function of the validated *cis* PGx-eQTLs across three different cell types using luciferase reporter gene assays ([Fig. 1](#F1){ref-type="fig"}, Step 6).

### Phase I: Hypothesis-Generating Phase. {#s14}

#### Phase I: Identification of differentially expressed genes after AHR ligand exposure. {#s15}

RNA-seq performed in eight cell lines after exposure to the AHR agonist 3-MC or the AHR antagonist GNF-351 identified 1865 genes that were significantly differentially expressed (FDR ≤0.05) after 3-MC treatment and 3664 genes that were significantly differentially expressed (FDR ≤0.05) after GNF-351 treatment ([Fig. 2, A and B](#F2){ref-type="fig"}). Sixty-nine genes were differentially expressed by at least 2-fold after either 3-MC or GNF-351 treatment ([Fig. 2C](#F2){ref-type="fig"}). Importantly, there was wide variation in the degree of differential expression for these 69 genes among the eight cell lines after exposure to GNF-351 or 3-MC. That variation may be due, in part, to genomic variation. To test the validity of the RNA-seq data, 15 of these 69 genes were validated by qRT-PCR in independent experiments using all eight LCLs that had been used to perform RNA-seq ([Supplemental Fig. 2](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)). Those validation genes were selected from three groups: 1) prototypic AHR-regulated genes (*CYP1A1*, *CYP1B1*, *AHRR*, and *TIPARP*), 2) immune-relevant genes (*RARRES2*, *IL2RA*, *IGF1*, *CXCL8*, and *CXCL12*), and 3) other differentially expressed genes selected at random (*SHF*, *WNT11*, *CRYM*, *GPR68*, *DMTN*, and *HES2*).

![LCL transcriptome after AHR activation (3-MC treatment) or inhibition (GNF-351 treatment). (A) A total of 1865 genes was differentially expressed after 3-MC treatment at a FDR \<0.05, but only 16 of those genes were differentially expressed by at least 2-fold. More genes had expression that increased after 3-MC treatment than those that decreased. (B) A total of 3664 genes was differentially expressed after GNF-351 treatment at a FDR \<0.05, but only 64 of those genes were differently expressed by at least 2-fold. (C) The figure shows a heatmap for the 69 genes that were differentially expressed by at least 2-fold with a FDR \<0.05 after either 3-MC or GNF-351 treatment, but their degree of differential expression was variable across LCLs. (D) The SNP-dependent effect of rs2470893 after 3-MC treatment was determined by both qRT-PCR and RNA-seq in the samples that were used for RNA-seq and represented in violin plot. Each group contained four lymphoblastoid cell lines. *P* values were calculated using a two-tailed Student's *t* test: \**P* \< 0.05; \*\* *P* \< 0.01; \*\*\**P* \< 0.001.](dmd.119.087312f2){#F2}

As a quality control measure, we next asked whether the previously identified rs2470893 SNP in the promoter of the *CYP1A1* gene ([@B37]) was a significant *cis* PGx-eQTL across the eight cell lines studied (four homozygous variant and four homozygous wild-type) based on our RNA-seq data. Consistent with our previous findings, the variant rs2470893 SNP genotype was associated with a greater increase in CYP1A1 expression than was the wild-type SNP genotype after 3-MC treatment compared with vehicle in these samples as tested by qRT-PCR (*P* = 0.001) and by RNA-seq (*P* = 0.006) ([Fig. 2D](#F2){ref-type="fig"}). These results indicated that the RNA-seq data were consistent with the qRT-PCR findings and, as a result, that RNA-seq has adequate sensitivity to detect *cis* PGx-eQTLs.

In summary, we identified 69 genes that were highly differentially expressed after AHR ligand exposure compared with vehicle, with considerable variation across the eight cell lines studied. This variation might be due, at least in part, to genetic variation.

#### Phase I: Identification of AHR binding sites. {#s16}

AHR ChIP-seq was performed using the GM17212 LCL to identify AHR binding regions across the genome in LCLs. Biologic replicates demonstrated a high degree of similarity based on the correlation coefficient for overlapping peak scores after either vehicle (*R*^2^ = 0.854, [Supplemental Fig. 3A](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)) or 3-MC treatment (*R*^2^ = 0.774, [Supplemental Fig. 3B](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)). A total of 17,535 peaks were in common across all of the samples studied, with just 904 peaks that were unique to the vehicle-treated samples and 810 peaks that were unique to the 3-MC--treated samples. Furthermore, the peaks unique to just 3-MC or vehicle treatment demonstrated less significant binding than did peaks that were in common across the LCLs (both *P* \< 2.2E-16, one-sided Mann-Whitney *U* test). Because most AHR-binding peaks were shared across all samples, and because the AHR-binding peaks unique to either 3-MC or vehicle exposure demonstrated less significant binding than did peaks shared across all samples, the peaks that were common to all of the samples were used for the downstream analyses shown graphically in [Fig. 1](#F1){ref-type="fig"} (Steps 2--6). The majority of these AHR-binding peaks were located within active promoters, strong enhancers, weak enhancers, or weak promoters ([Supplemental Fig. 3C](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)), as defined by ChromHMM states developed in a LCL (GM12878) ([@B10]; [@B9]).

The high degree of AHR-binding peak overlap between vehicle- and agonist-treated samples has been demonstrated previously in studies performed with breast cancer cell lines ([@B63]) and may result from the fact that endogenous compounds such as kynurenine and its metabolites are known ligands for AHR ([@B50]). Furthermore, AHR is highly expressed in LCLs---even more highly expressed than in the liver ([Supplemental Fig. 4A](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)), where it plays an important role in xenobiotic and drug metabolism ([@B55]; [@B67]). Furthermore, we observed a striking decrease in the expression of AHR-regulated genes from our panel of differentially expressed genes after AHR knockdown indicated that AHR regulated the expression of these genes at baseline ([Supplemental Fig. 4B](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)).

As the next step, to test the validity of the AHR ChIP-seq results, we applied the Discriminative Regular Expression Motif Elicitation (DREME-Tomtom) software from the MEME suite, which identified short *de novo* motifs that were highly represented in the ChIP-seq peaks, and then compared those *de novo*motifs with known transcription factor--binding motifs ([@B1]). One of the top *de novo* motifs in our ChIP-seq peaks identified by DREME (E-value = 6.2E−65) was 5′-DCACGCA-3′, which was identified 1752 times in 1506 peaks. This 7-bp *de novo* motif was most similar to the 5-bp canonical AHR-binding motif (5′-CACGC-3′) ([@B32]) when compared with all known motifs in the HOCOMOCO database (*P* value = 1E--05) ([Supplemental Fig. 5](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)). Some of the other highly represented DNA sequences included motifs for TFs that have previously been shown to interact with AHR such as SP1 ([@B28]; [@B61]) and signal transducer and activator of transcription 5 (STAT5) ([@B25]).

#### Phase I: Identification of putative cis PGx-eQTLs. {#s17}

We next attempted to identify *cis* PGx-eQTLs from across the genome that did not create/destroy AHREs in ChIP-seq--identified AHR-binding peaks by testing SNPs for their association with variation in the 69 highly differentially expressed genes (FDR ≤0.05, \|fold change\| ≥2) that we had identified after exposure to either 3-MC or GNF-351 as compared with vehicle ([Fig. 2C](#F2){ref-type="fig"}). Fifty-four of the 69 highly differentially expressed genes (78.3%) contained at least one AHR ChIP-seq--binding peak within 50 kb of the gene, which supported the possibility that those genes might be directly regulated by AHR. Thirty-eight of those AHR-binding peaks had at least one SNP (MAF ≥0.25) within 500 bp of the peak (measured from each end of the peak) that was not an eQTL for that gene under basal conditions, as reported by GTEx ([@B4]). Of the 212 SNPs within 500 bp of the AHR-binding peaks, 36 SNPs at 19 loci were associated with variation in RNA-seq--based differential gene expression after exposure to 3-MC or GNF-351 relative to vehicle, thus raising the possibility that they might be *cis* PGx-eQTLs. A locus was defined as a single SNP or multiple SNPs that were in tight linkage disequilibrium (LD) (*R*^2^ \> 0.8) that was associated with variation in differential gene expression after ligand exposure as compared with vehicle. Each of those 19 loci included between 1 and 10 SNPs in tight LD (*R*^2^ \> 0.8). Most loci included just one AHR-binding peak, but one locus (in intron 4 of the *AHRR* gene) included three AHR-binding peaks because the tightly linked SNPs that were associated with variation in AHRR differential expression after exposure to 3-MC mapped across multiple peaks ([Supplemental Table 4](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)). Having identified a group of potential *cis* PGx-eQTLs by applying the strategy outlined in [Fig. 1](#F1){ref-type="fig"}, we were ready to move to the functional genomics phase of the study.

### Phase II: Functional Genomics Phase. {#s18}

#### Phase II: Validation of putative cis PGx-eQTLs. {#s19}

Of the 19 putative *cis* PGx-eQTLs that we had identified ([Supplemental Table 4](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)), four \[AMZ1 (two separate linkage blocks), LOC151484, and TPRG1\] were not included in the validation experiments because we were unable to identify specific primer sets to perform qRT-PCR (at least three primer sets were tested for each RNA). Of the remaining 15 putative *cis* PGx-eQTLs, 10 showed significant variation in SNP genotype-dependent gene expression after exposure to 3-MC or GNF-351 relative to vehicle in additional LCLs that were selected based on the SNP genotype for each independent *cis* PGx-eQTL ([Fig. 3](#F3){ref-type="fig"}; [Supplemental Table 4](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)). Those 10 validated loci included 25 SNPs across 11 AHR-binding peaks that were associated with variation in differential gene expression after either 3-MC or GNF-351 exposure. Six of the 10 validated *cis* PGx-eQTLs were 3-MC dependent ([Fig. 3A](#F3){ref-type="fig"}), and four were GNF-351 dependent ([Fig. 3B](#F3){ref-type="fig"}). None of the *cis* PGx-eQTLs that we identified were both 3-MC dependent and GNF-351 dependent, which means that the SNPs that were associated with variation in gene expression after 3-MC exposure relative to vehicle were different from the SNPs that were associated with variation in gene expression after GNF-351 exposure. The variation in expression of three genes following ligand exposure were associated with two independent *cis* PGx-eQTLs for each of the genes---*AHRR*, *TMEM119*, and *STK32C*. One of the *AHRR cis* PGx-eQTLs was 3-MC dependent, whereas the other was GNF-351 dependent; both of the *TMEM119 cis* PGx-eQTLs were 3-MC dependent; and both of the *STK32C cis* PGx-eQTLs were GNF-351 dependent ([Fig. 3](#F3){ref-type="fig"}). Whenever possible, for the genes that had two independent *cis* PGx-eQTLs, we selected cell lines that were homozygous wild-type at one locus while varying the SNP genotype at the other locus. Therefore, we identified 10 *cis* PGx-eQTLs, which included 25 SNPs across 11 AHR-binding peaks where SNP-by-treatment interactions altered the degree of AHR-regulated gene differential expression after exposure to either 3-MC or GNF-351 relative to vehicle. A canonical AHRE core motif (5′-CACGC-3′)---the DNA sequence that is recognized to be bound by AHR---was identified in 8 of the 11 AHR ChIP-seq--binding peaks that were present in 7 of the 10 *cis* PGx-eQTLs ([Supplemental Table 4](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)).

![Validation of PGx-eQTL. Nine of the 15 testable putative PGx-eQTLs were validated by qRT-PCR, and one was suggestive. (A) Six validated PGx-eQTL loci were 3-MC dependent and (B) four validated PGx-eQTLs were GNF-351 treatment dependent. None of the loci were both 3-MC and GNF-351 treatment dependent. When possible, cell lines that were either homozygous variant (red) or homozygous wild-type (blue) were used to test differential expression. When unavailable (TMEM119-rs880844) or when a suggestive *P* value was detected (RARRES2-4*--*linked SNPs), cell lines heterozygous for those SNPs were used. All tests for significance used a two-tailed Student's *t* test, and ANOVA was used across the three genotypes for the RARRES2 locus. The number of samples (*N*) for each group is at the bottom of the *x*-axis for each plot. \**P* \< 0.05; \*\**P* \< 0.01.](dmd.119.087312f3){#F3}

We also asked whether the 11 AHR binding sites across the 10 *cis* PGx-eQTLs (defined by SNP LD *R*^2^ \> 0.8) might be functional in cell types other than LCLs by determining whether they were in genomic regions that were active or inactive across different cell types as defined by the epigenome roadmap ([@B30]). Active regions are those that are associated with expressed genes (i.e., enhancers and transcriptionally active sites), and inactive regions are those that are not associated with gene expression (i.e., heterochromatin and repressed polycomb states). Five of the 11 *cis* PGx-eQTL AHR-binding peaks were in genomic regions that were active across most cell types ([Supplemental Fig. 6A](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)). Five of the 11 *cis* PGx-eQTL AHR-binding peaks were in regions that were highly variable both across cell types and across cell lines within each cell type ([Supplemental Fig. 6B](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)). Only 1 of the 11 *cis* PGx-eQTL AHR-binding peaks was in an inactive genomic region across most cell types ([Supplemental Fig. 6C](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)). These observations indicate that many of these loci might be *cis* PGx-eQTLs in many tissues beyond just LCLs because the *cis* PGx-eQTL AHR-binding peaks fell within active regions across many cell types.

Therefore, we had identified 10 SNP loci that were not eQTLs under basal conditions, but that were *cis* PGx-eQTLs dependent on exposure to either the AHR agonist 3-MC or the AHR antagonist GNF-351. Those loci included 11 AHR-binding peaks and 25 SNPs that were associated with variation in differential gene expression of seven genes following 3-MC or GNF-351 exposure---none of which contained SNPs that interrupted a functional AHRE canonical motif. In addition, many of the *cis* PGx-eQTLs mapped to genomic regions that were active across many different cell types, raising the possibility that those loci may be *cis* PGx-eQTLs in additional cell types. All of these observations supported our original hypothesis that there might be additional SNPs near AHR-regulated genes that function as *cis* PGx-eQTLs in an AHR ligand-dependent fashion across the genome beyond the original SNP (rs2470893) that we had identified in the promoter of the *CYP1A1* gene ([Fig. 2D](#F2){ref-type="fig"}).

#### Phase II: Functional investigation of the identified AHR cis PGx-eQTLs. {#s20}

We next set out to determine whether these 10 validated *cis* PGx-eQTLs were functional across different cell types by using luciferase reporter gene plasmids for all 10 of the *cis* PGx-eQTLs ([Fig. 3](#F3){ref-type="fig"}). Those 10 loci included 25 SNPs across 11 peaks, which resulted in 12 SNP-peak regions. These 12 regions included one peak that was surrounded by two independent SNP LD blocks (*R*^2^ = 0.324) that were associated with variation in GNF-351--dependent *STK32C* gene expression and one SNP LD block that was associated with variation in 3-MC dependent *AHRR* gene expression that spanned three AHR-binding peaks over a 8944-bp genomic region ([Supplemental Table 4](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)). Variant and wild-type luciferase reporter gene constructs were generated for each *cis* PGx-eQTL peak region, and differential luciferase activity was determined relative to a pRL renilla transfection control vector. We tested the luciferase reporter gene constructs in three different cell types: LCL (GM17212), HMC3 microglia-derived cells, and HepG2 hepatic carcinoma-derived cells. We selected these cell lines because AHR is an important regulator of the immune response (LCL and HMC3) and because it plays an important role in xenobiotic metabolism in the liver (HepG2). For purposes of brevity, we only provide detailed results from the luciferase experiments in the main text for three of the *cis* PGx-eQTLs---one associated with 3-MC--dependent *CYP1A1* expression and two associated with variation in ligand-dependent *AHRR* expression---because *CYP1A1* and *AHRR* are prototypic targets of AHR. Results for the other *cis* PGx-eQTLs are described in a more concise manner in the main text with detailed results provided in the figure legends.

#### Functional investigation of CYP1A1 rs3826041 cis PGx-eQTL with luciferase reporter gene assays. {#s21}

During the present studies, we identified a new *cis* PGx-eQTL SNP (rs3826041) in the promoter of the *CYP1A1* gene. *CYP1A1* is a prototypic target for AHR gene regulation and plays an important role in drug and xenobiotic metabolism. Binding profiles of AHR ChIP-seq--binding peaks within 50 kb of the *CYP1A1* gene, including the peak near the *cis* PGx-eQTL SNP for this gene (indicated with an asterisk) are shown in [Supplemental Fig. 7](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1). The rs3826041 SNP in the promoter region of the *CYP1A1* gene ([Fig. 3A](#F3){ref-type="fig"}) was not in LD with the rs2470893 SNP (*R*^2^ = 0.079), which we had previously described as a *cis* PGx-eQTL ([@B37]), and the rs3826041 SNP had a smaller effect on CYP1A1 3-MC--dependent differential expression (Cohen's *d* = 1.0) than did the SNP that we had reported previously (rs2470893; Cohen's *d* = 2.0). Furthermore, we previously reported that the rs2470893 SNP was 196 bp from a putative canonical AHRE motif (not shown in [Fig. 4A](#F4){ref-type="fig"}) ([@B37]), but the ChIP-seq data included in this manuscript showed that there was no AHR binding at that putative AHRE, indicating that it was not a functional AHRE in LCLs. Our AHR ChIP-seq data showed that the rs2470893 SNP was 466 bp from the nearest AHR-binding peak and 471 bp from the nearest AHRE located within that binding peak ([Fig. 4A](#F4){ref-type="fig"}).

![Functional validation of the *CYP1A1* PGx-eQTL. (A) One SNP (rs3826041) in a ChIP-seq*--*identified AHR-binding peak in the promoter of the *CYP1A1* gene was identified as a putative PGx-eQTL after 3-MC treatment. The rs3826041 SNP was different from the rs2470893 SNP previously described, and rs3826041 was within an AHR ChIP-seq peak, but was located 34 bp from an AHRE core motif (that was located within peak 5563). (B) The variant genotype for rs3826041 was associated with a smaller increase in CYP1A1 expression after 3-MC treatment as compared with the wild-type genotype. (C) Luciferase plasmids that contained the variant rs3826041 genotype and AHR-binding region, but not rs2470893 (indicated by dotted lines), demonstrated a smaller increase in luciferase activity after 3-MC treatment in LCLs, HepG2, and HMC3 cells when compared with luciferase plasmids containing the wild-type genotype for rs3826041. RNA expression significance was tested with a two-tailed Student's *t* test, and luciferase significance was tested with a one-tailed Student's *t* test. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001.](dmd.119.087312f4){#F4}

The new rs3826041 *CYP1A1 cis* PGx-eQTL SNP was located in an AHR-binding peak, but was 34 bp distant from an AHR core-binding motif (5′-CACGC-3′), indicating that it did not disrupt the AHRE DNA motif recognized by AHR ([Fig. 4A](#F4){ref-type="fig"}). The rs3826041 variant SNP genotype was associated with a smaller increase in CYP1A1 expression after 3-MC treatment ([Fig. 4B](#F4){ref-type="fig"}), an observation that was confirmed by luciferase reporter gene assays in LCLs and HMC3 cells. The variation in luciferase activity was suggestive in HepG2 cells (*P* = 0.08) ([Fig. 4, C](#F4){ref-type="fig"}). The luciferase reporter gene constructs that were used to investigate the rs3825041 SNP effect did not contain the previously identified rs2470893 SNP. Therefore, we identified a new *CYP1A1 cis* PGx-eQTL and had demonstrated that it was functional by luciferase reporter gene assays performed in three cell lines.

#### Functional investigation of AHRR cis PGx-eQTL SNPs with luciferase reporter gene assays. {#s22}

*AHRR* is another prototypic gene that is transcriptionally regulated by AHR. AHRR is the repressor of AHR and, therefore, provides crucial negative feedback to modulate AHR activation. The *AHRR* gene was the only gene to display both 3-MC--dependent and GNF-351--dependent *cis* PGx-eQTLs at two independent loci. AHR ChIP-seq--binding profiles within 50 kb of the *AHRR* gene, including those near *cis* PGx-eQTL SNPs (indicated with asterisks), are shown in [Supplemental Fig. 8](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1). The first *AHRR cis* PGx-eQTL---in intron 3 of the *AHRR* gene---included one SNP (rs1877843) that was 241 bp away from AHR-binding peak 13160 and was associated with variation in AHRR expression after GNF-351 exposure relative to vehicle ([Fig. 5A](#F5){ref-type="fig"}). Therefore, we used luciferase reporter gene assays to study this locus in different cell types.

![Functional investigation of the *AHRR* GNF-351--dependent PGx-eQTL. (A) The GNF-351--dependent PGx-eQTL for *AHRR* was in intron 3 of the *AHRR* gene and contained rs1877843, which was 241 bp from peak 13160. (B) The variant rs1877843 SNP genotype was associated with a larger decrease in AHRR expression after GNF-351 treatment than the wild-type SNP genotype. (C) Luciferase plasmids that contained the variant SNP genotypes for rs1877843 and rs1877840 demonstrated a larger decrease in luciferase activity after GNF-351 treatment compared with luciferase plasmids containing the wild-type SNP genotypes in all three cell lines. The number of samples (*N*) for each group is at the bottom of each plot. All tests for significance used a two-tailed Student's *t* test. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001.](dmd.119.087312f5){#F5}

Variant genotypes for the SNPs near AHR-binding peak 13160 (rs1877843 and rs1877840) in intron 3 of the *AHRR* gene ([Fig. 5A](#F5){ref-type="fig"}) were associated with a larger decrease in AHRR expression after GNF-351 treatment than was observed for the wild-type genotype ([Fig. 5B](#F5){ref-type="fig"}). This effect was consistent in all three cell lines---LCLs, HepG2, and HMC3 ([Fig. 5C](#F5){ref-type="fig"}). These data indicate that this locus is a functional *cis* PGx-eQTL and that it has the potential to act functionally in cell types beyond just LCLs.

The other AHRR *cis* PGx-eQTL---which mapped to intron 4 of the *AHRR* gene---contained 10 tightly linked SNPs (*R*^2^ ≥ 0.88) across three AHR-binding peaks ([Fig. 6A](#F6){ref-type="fig"}). Variant genotypes for these 10 SNPs were associated with higher AHRR expression relative to the wild-type genotypes after 3-MC exposure ([Fig. 6B](#F6){ref-type="fig"}). The distances between the three AHR-binding peaks in this locus were large enough (6687 bp and 2284 bp) to permit the generation of separate luciferase plasmids for each AHR-binding peak together with the surrounding *cis* PGx-eQTL SNPs---thus making it possible to study and identify the three groupings of SNPs around each individual AHR-binding peak that comprised this *cis* PGx-eQTL, which included a large LD block.

![Functional investigation of the *AHRR* 3-MC--dependent PGx-eQTL. (A) The 3-MC--dependent PGx-eQTL for *AHRR* included 10 SNPs across peaks 13161, 13163, and 13164 in intron 4 of the *AHRR* gene. (B) The variant SNP genotypes for the 10 linked SNPs that were across three AHR-binding peaks in intron 4 of the *AHRR* gene were associated with an increase after 3-MC treatment, and the wild-type was associated with a decrease after 3-MC treatment. (C) The luciferase plasmid that contained the variant SNP genotypes for the SNPs surrounding peak 13161 (as indicated by the dashed lines) demonstrated no difference in LCLs or HepG2 cells and a smaller increase than the wild-type SNP genotype in HMC3 cells, which was suggestive. (D) The luciferase plasmid that contained the variant genotypes for the five SNPs near peak 13163 in intron 4 of the *AHRR* gene (as indicated by the dashed lines) demonstrated a larger increase in luciferase activity after 3-MC treatment than the wild-type in LCLs, HepG2, and HMC3---the same direction observed for differential expression in LCLs. (E) The luciferase plasmid that contained the variant genotype for rs872848 and peak 13164 (indicated by the dashed lines) demonstrated no difference in luciferase activity in LCLs, but showed a smaller decrease than did the plasmid that contained the wild-type genotype for rs872848 with peak 13164 in HepG2 and displayed a larger increase in luciferase activity in HMC3. The number of samples (*N*) for each group is at the bottom of each plot. All tests for significance used a two-tailed Student's *t* test. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001.](dmd.119.087312f6){#F6}

The luciferase plasmids that contained AHR-binding peak 13161 did not demonstrate a SNP-by-treatment--dependent effect in any of the three cell lines studied (LCLs, HepG2 cells, or HMC3 cells) ([Fig. 6C](#F6){ref-type="fig"}). This result indicates that the four SNPs surrounding AHR-binding peak 13161 may not contribute to the SNP-by-treatment--dependent variation in 3-MC--dependent AHRR expression observed by qRT-PCR ([Fig. 6B](#F6){ref-type="fig"}) and that the SNPs that confer this SNP-by-treatment--dependent variation in gene expression may be those around AHR-binding peak 13163 or AHR-binding peak 13164 ([Fig. 6A](#F6){ref-type="fig"}). Alternatively, the SNPs near AHR peak 13161 may operate over longer distances via peaks not included in this reporter construct or may require three-dimensional chromatin organization.

Indeed, the luciferase plasmids that contained AHR-binding peak 13163 with the surrounding SNPs ([Fig. 6A](#F6){ref-type="fig"}) demonstrated SNP-by-treatment--dependent variation in luciferase activity following 3-MC treatment, and the responses were consistent in all three cells lines studied (LCLs, HepG2 cells, and HMC3 cells). The variant SNP genotypes demonstrated a larger increase in luciferase activity than the wild-type SNP genotypes after 3-MC treatment ([Fig. 6D](#F6){ref-type="fig"}). These results indicate that AHR-binding peak 13163 together with the surrounding SNPs is functional and may contribute to the SNP-by-treatment--dependent variation in AHRR expression observed by qRT-PCR ([Fig. 6B](#F6){ref-type="fig"}).

In addition, luciferase plasmids that contained peak 13164 and SNP rs872848 demonstrated a SNP-by-treatment--dependent variation in luciferase activity in HepG2 cells and HMC3 cells, but not in LCLs ([Fig. 6E](#F6){ref-type="fig"}). However, the direction of this differential expression from baseline was not the same in all three cell lines for this region. Specifically, luciferase activity decreased in HepG2 cells following 3-MC exposure, but increased in HMC3 cells following 3-MC treatment. Even though the luciferase activity increased in HMC3 cells and decreased in HepG2 cells, the SNP-dependent effect was maintained, because the variant genotype demonstrated a larger increase after 3-MC treatment in HMC3 cells and a smaller decrease after 3-MC treatment in HepG2 cells ([Fig. 6E](#F6){ref-type="fig"}). Therefore, peak 13164 and SNP rs872848 may contribute to the SNP-by-treatment--dependent variation observed for this locus, but only in specific cell types.

Therefore, this locus, which included 10 tightly linked SNPs across three AHR-binding peaks, demonstrated strong cell line--specific and SNP-by-treatment--dependent effects on gene expression. Specifically, the regions of this locus that included peak 13163 with the surrounding SNPs and peak 13164 with rs872848 both demonstrated SNP-by-treatment--dependent variation in luciferase activity, which suggests that they may both contribute to the overall SNP-by-treatment--dependent variation observed by qRT-PCR ([Fig. 6B](#F6){ref-type="fig"}). The observed cell line--dependent effects may be due to differences in the cellular environment within each cell type, which could include differences in chromatin organization or differences in the expression of coregulator proteins that bind in a complex with AHR.

#### Functional investigation of additional cis PGx-eQTL SNPs with luciferase reporter gene assays. {#s23}

The other seven *cis* PGx-eQTL genes functionally validated by qRT-PCR (see [Fig. 3](#F3){ref-type="fig"}) were not prototypic AHR targets, but included several immune-related genes (*RARRES2*, *TMEM119*, and *ASB2*). We also studied generalizability across cell lines for these seven *cis* PGx-eQTLs by using luciferase reporter gene assays in LCLs, HepG2 cells, and HMC3 cells. Six of those seven *cis* PGx-eQTLs demonstrated SNP-by-treatment--dependent variation in luciferase activity following ligand exposure.

We first investigated the two 3-MC--dependent TMEM119 *cis* PGx-eQTLs that were 3′ of the *TMEM119* gene. These SNPs were not in LD (*R*^2^ = 0.154) ([Supplemental Fig. 9A](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)). The *cis* PGx-eQTL that contained peak 3966 and SNP rs2287555 demonstrated a significant SNP-by-treatment--dependent variation in luciferase activity in HMC3 cells, where the variant SNP genotype was associated with decreased luciferase activity compared with the wild-type SNP genotype following 3-MC exposure---opposite to the LCL qRT-PCR results ([Supplemental Fig. 9B](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)). No significant variation was observed in LCLs or HepG2 cells ([Supplemental Fig. 9C](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)). The *cis* PGx-eQTL that included peak 3967 and SNP rs880844 demonstrated SNP-by-treatment--dependent variation in luciferase activity in all three cell lines ([Supplemental Fig. 9D](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)). However, consistent with the qRT-PCR results, the variant rs880844 SNP was associated with higher luciferase activity than the wild-type SNP genotype following 3-MC treatment in LCLs ([Supplemental Fig. 9D](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)). However, the variant rs880844 SNP genotype was associated with lower luciferase activity than observed for the wild-type SNP genotype in both HMC3 and HepG2 cells ([Supplemental Fig. 9E](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)).

The 3-MC--dependent RARRES2 *cis* PGx-eQTL mapped 3′ of the *RARRES2* gene and included peak 15754 and four tightly linked SNPs (*R*^2^ = 1) ([Supplemental Fig. 10A](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)). The luciferase assays demonstrated SNP-by-treatment--dependent variation in luciferase activity for which variant SNP genotypes were associated with higher expression than were wild-type SNP genotypes following 3-MC exposure in HepG2 cells and LCLs (suggestive *P* = 0.06; [Supplemental Fig. 10C](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)). Those results were consistent with the LCL qRT-PCR results ([Supplemental Fig. 10B](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)). However, a similar response was not observed in HMC3 cells ([Supplemental Fig. 10C](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)).

The 3-MC--dependent ASB2 *cis* PGx-eQTL that mapped to intron 1 of the *ASB2* gene ([Supplemental Fig. 11A](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)) demonstrated SNP-by-treatment--dependent variation in luciferase activity in all three cell lines studied. Consistent with the LCL qRT-PCR results ([Supplemental Fig. 11B](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)), the variant rs941490 SNP genotype was associated with higher luciferase activity compared with the wild-type SNP genoptype following 3-MC exposure in LCLs and HepG2 cells, but the variant SNP genotype was associated with lower luciferase activity compared with the wild-type SNP genotypes in HMC3 cells ([Supplemental Fig. 11C](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)).

We also identified SNP-by-treatment--dependent variation in luciferase activity for both of the GNF-351--dependent STK32C *cis* PGx-eQTLs in exon 1 of the *STK32C* gene ([Supplemental Fig. 12A](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)). The rs11146335 SNP was not in LD (*R*^2^ ≤ 0.32) with the other four SNPs, all of which were tightly linked (*R*^2^ ≥ 0.96). The *cis* PGx-eQTL that included peak 2391 and rs11146335 SNP, which was in the AHR-binding peak but was not in an AHRE, demonstrated SNP-by-treatment--dependent variation in luciferase activity following GNF-351 exposure in all three cell lines studied. Consistent with the LCL qRT-PCR results ([Supplemental Fig. 12B](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)), the variant rs11146335 SNP genotype was associated with lower luciferase activity compared with the wild-type SNP genotype in HepG2 cells, but the variant SNP genotype was associated with higher expression compared with the wild-type SNP genotype in LCLs and HMC3 cells ([Supplemental Fig. 12C](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)). The *STK32C cis* PGx-eQTL that included the four linked SNPs around peak 2391 demonstrated SNP-by-treatment--dependent variation in luciferase activity in LCLs in which variant SNP genotypes were associated with higher luciferase activity compared with wild-type SNP genotypes, which was consistent with the LCL qRT-PCR expression results ([Supplemental Fig. 12D](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)). However, a significant variation in luciferase activity was not observed in HMC3 or HepG2 cells ([Supplemental Fig. 12E](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)).

Finally, no SNP-by-treatment--dependent variation in luciferase activity was observed for the GNF-351 *C17orf99 cis* PGx-eQTL in any of the three cell lines studied (LCLs, HMC3, or HepG2; data not shown). It should be emphasized that this does not necessarily mean that this locus is not a *cis* PGx-eQTL, but rather that our in vitro assay, which lacks genomic context, was unable to detect a *cis* PGx-eQTL relationship. For example, the genomic context required to detect the effect might include the effects of three-dimensional chromatin organization or genomic regions that are required for the binding of coregulators.

In summary, three of the 10 validated *cis* PGx-eQTLs demonstrated SNP-by-treatment--dependent variation in luciferase activity that was consistent across all three different cell lines that we studied and was also consistent with the qRT-PCR results for LCLs. An additional three loci demonstrated SNP-by-treatment--dependent variation in luciferase activity across all three cell lines, but with opposite SNP-dependent effects in one of the cell lines studied. One of the 10 loci demonstrated a SNP-by-treatment--dependent variation in luciferase activity in two of the three cell lines, and two of the *cis* PGx-eQTLs demonstrated SNP-by-treatment--dependent variation in luciferase activity in only one of the three cell lines studied. Finally, only one locus failed to demonstrate SNP-by-treatment--dependent variation in luciferase activity in any of the cell lines studied. These results clearly demonstrate that cellular context is an important contriubutor to the functional implications of these *cis* PGx-eQTLs.

Discussion {#s24}
==========

We have described a novel type of eQTL in which SNPs at a distance from AHR binding sites are associated with interindividual variation in target gene expression in a ligand-by-genotype--dependent fashion. Our findings indicate that SNPs across the genome that do not create/destroy an AHRE can, nonetheless, demonstrate an AHR-dependent SNP-by-drug interaction that results in variation in the degree or direction of target gene expression following exposure to AHR ligands. However, those SNPs are not associated with variation in gene expression in the absence of AHR ligand treatment, so their functional impact is only detected in the presence of drug. We refer to these SNPs as PGx-eQTLs because they involve SNPs that are associated with variation in expression after drug or xenobiotic treatment. PGx-eQTLs include SNPs in transcription factor core--binding motifs as well as SNPs that are distant from transcription factor core motifs. However, in this study, we focused solely on SNPs that were outside of functional AHREs. These findings are potentially important because \>90% of SNPs that are significantly associated with phenotypes (including PGx phenotypes) that have been identified during GWAS have mapped to noncoding regions of the genome ([@B18]; [@B12]; [@B56]), but only 25.6% of GWAS SNPs are also eQTLs in the GTEx database (v7) ([@B4]; [@B43]). Thus, the function of many clinically relevant SNPs remains unclear. Indeed, previous reports indicated that some SNPs only demonstrate associations with gene expression under specific conditions, such as exposure to drugs or other exogenous compounds ([@B33]; [@B14]; [@B41], [@B37]; [@B11]; [@B45]; [@B67]; [@B17]; [@B27]). The novelty of the results presented in this manuscript lies in 1) the genome-wide approach, which allowed identification of many novel *cis* PGx-eQTLs, and 2) our focus on SNPs that did not create/destroy functional AHREs, but still altered AHR ligand-dependent target gene expression.

Of interest is the fact that we identified different *cis* PGx-eQTLs after exposure to 3-MC (an AHR agonist) and GNF-351 (an AHR antagonist) ([Fig. 3](#F3){ref-type="fig"}), possibly because different ligands may result in different AHR conformations that could potentially impact the effect of coregulatory protein complex interactions. Furthermore, many of those *cis* PGx-eQTLs were in active genomic regions across multiple cell types, and our luciferase assays demonstrated that some of the *cis* PGx-eQTLs were consistent across all cell types studied, whereas other loci were not.

We observed four general types of *cis* PGx-eQTLs: 1) *cis* PGx-eQTLs that were highly consistent across the three different cell types that we studied (LCLs, HMC3, and HepG2); 2) *cis* PGx-eQTLs that demonstrated opposing directions of differential expression in some cell lines regardless of SNP genotype; 3) *cis* PGx-eQTLs that demonstrated SNP-dependent effects in some, but not all of the cell lines studied; and 4) *cis* PGx-eQTLs that resulted in different directionality for some of the cell lines. The different directions for differential expression as well as the variation in SNP-dependent effects after the same treatment in different cell lines may be due to variation in the sensitivity of those cell lines to these exogenous compounds or to variation in the cellular environment such as the epigenetic landscape, including chromatin looping or variation in the expression of proteins, such as TF coregulators in different cell types.

Of interest, 4 of the 10 validated *cis* PGx-eQTLs that we identified were previously associated with drug and environment interaction phenotypes. The rs3826041 *cis* PGx-eQTL SNP in the promoter of the *CYP1A1* gene ([Fig. 6A](#F6){ref-type="fig"}) or SNPs in tight LD with that SNP (rs4886605, *r*^2^ = 0.87; rs1456432, *r*^2^ = 0.87) were previously associated with variability in coronary artery disease risk in Uygur men ([@B68]), variation in warfarin response ([@B42]), and in hepatocellular carcinoma risk ([@B34]). In another study, the same SNPs were associated with risk for testicular germ cell tumors and variation in oxychlorodane concentration, a chemical that has been associated with AHR activation ([@B48]). Therefore, activation of AHR by oxychlorodane could alter CYP1A1 expression through this *cis* PGx-eQTL and could, hypothetically, lead to altered risk for testicular germ cell tumors.

In addition, the rs2671903 *cis* PGx-eQTL SNP in intron 4 of the *AHRR* gene near peak 13161 ([Fig. 5A](#F5){ref-type="fig"}) has previously been associated with variation in CpG methylation in cigarette smokers versus nonsmokers, which indicated a gene-by-environment interaction that resulted in significant variation in AHRR expression ([@B58]). Cigarette smoke is known to contain polycyclic aromatic hydrocarbons that are AHR agonists, which could result in SNP-dependent AHRR variation in expression in response to cigarette smoke at this *cis* PGx-eQTL ([@B60]).

The rs880844 *cis* PGx-eQTL SNP 3′ of the *TMEM119* (Supplemental Fig. 9) gene has been suggestively associated with rheumatoid arthritis risk. Of importance, AHR activity has been associated with rheumatoid arthritis as well as with increased risk for rheumatoid arthritis in smokers; and AHR activity has been demonstrated to contribute to rheumatoid arthritis severity in animal models through the modulation of environmental stimuli ([@B46]; [@B23]; [@B59]; [@B13]).

Finally, the SNPs that were in tight LD (*r*^2^ \> 0.8) with the *RARRES2 cis* PGx-eQTL SNPs have previously been associated with variation in body mass index, metabolic, and inflammatory diseases and levels of chemerin ([@B57]) (the protein encoded by the *RARRES2* gene). Chemerin is mainly expressed in adipose tissues and is an inflammatory modulator associated with metabolic and inflammatory diseases. AHR is known to modulate inflammatory response, and AHR is very highly expressed in both adipose tissue types reported by GTEx ([Supplemental Fig. 4A](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.119.087312/-/DC1)). Therefore, regulation of RARRES2 by the AHR *cis* PGx-eQTL could have implications for metabolic and inflammatory diseases ([@B44]; Tonjes et al., 2014; [@B8]).

In summary, the AHR-based *cis* PGx-eQTLs studied in this work have demonstrated : 1) that *cis* PGx-eQTLs can be observed at multiple loci across the genome---at least for AHR; 2) that multiple *cis* PGx-eQTLs can regulate the expression of the same gene; 3) that there are cell line--dependent effects on differential expression after the same treatment; 4) that *cis* PGx-eQTLs can have different functional effects in different cell types; and 5) that *cis* PGx-eQTLs have potential clinical utility, including for drug response phenotypes. These results suggest that AHR *cis* PGx-eQTLs may play a role in disease pathophysiology and in response to drug therapy or xenobiotic exposure.

Obviously, this study has not resulted in an exhaustive list of AHR ligand--dependent PGx-eQTLs, but this series of experiments has provided evidence that SNPs across the genome that are at a distance from AHREs can influence AHR ligand--dependent expression. Based on the results of our previous studies, these SNPs may interact with coregulator(s) that binds to AHR to form a larger complex and may alter complex stability binding at that locus ([@B41], [@B37]; [@B67]; [@B17]; [@B51]). Future studies aimed at understanding AHR PGx-eQTLs should focus on identifying mechanisms underlying the function of these SNPs and mechanisms responsible for their cell-specific effects.

Finally, there are many ligand-activated TFs other than AHR that have clinical relevance, including estrogen receptor *α*, androgen receptor, and glucocorticoid receptor, for which PGx-eQTLs might influence ligand-dependent expression and alter response to nuclear receptor--targeted drugs. Therefore, the present study represents only an initial step toward future studies of PGx-eQTLs designed to enhance our understanding of the molecular basis for this type of interindividual variation in gene expression, variation that might influence response after exposure to drugs or other xenobiotics. In summary, the data presented in this manuscript suggest that interindividual variation in response to drugs and xenobiotics that act as ligands for ligand-activated TFs may be due, in part, to SNP genotypes that are outside of ligand-activated TF binding sites. This functional SNP genotype information might potentially be used to predict and alter drug therapy response, i.e., for PGx purposes. The present results have clearly demonstrated that PGx-eQTLs differ from, but are complementary to, baseline eQTLs. Future studies should help us better understand how polymorphisms in noncoding regions of the genome might contribute to variation in gene expression after exposure to exogenous compounds and, as a result, how they might contribute to variation in drug response.
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